RIPK1 and amyotrophic lateral sclerosis: In parallel, there is a decrease in the expression of the endogenous RIPK1 inhibitor TANK-binding kinase 1 (TBK1), which leads to neuroinflammation, additional TDP-43 aggregation, axonal degeneration, loss of neurons and behavioral deficits, and the further manifestation of signs of ALS and FTD (Freischmidt et al., 2017).